TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6894708
Drug: Sustained Release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained Release (SR) formulation of butriptyline, 75 mg single oral dose
Study: 6894708
Drug: Conventional formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional formulation of butriptyline, 75 mg single oral dose
Study: 19329279
Drug: Novel compounds
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel compounds for SLE treatment
Study: 17523483
Drug: Interferon preparations
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon preparations included in complex therapy for ureaplasmosis
Study: 11881128
Drug: Candesartan 16
Normalized name: candesartan 16 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan 16 mg o.d. for 24 weeks
Study: 9773913
Drug: Propofol (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (2.5 mg x kg(‐1); 15 mg x kg(‐1) x hr)
Study: 2149513
Drug: Labetalol (1600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol (1600 mg max daily dose)
Study: 2149513
Drug: Propranolol (640
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (640 mg max daily dose)
Study: 28183544
Drug: 0.45 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.45 mg/kg rocuronium plus magnesium sulfate 30 mg/kg (group LM)
Study: 28183544
Drug: 0.6 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg/kg rocuronium (group C)
Study: 28183544
Drug: 0.45 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.45 mg/kg rocuronium (group LR)
Study: 23591713
Drug: Cholecalciferol 7,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol 7,000 IU daily for 26 weeks
Study: 19669785
Drug: Oral prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisone (Cor, Cortancyl, 50 mg per day for 1 week)
Study: 19669785
Drug: Oral prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisone (Cor)
Study: 8198020
Drug: Fluvastatin 20
Normalized name: fluvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 20 mg/d + Niacin (titrated to maximum of 3 g/d)
Study: 3556263
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg paracetamol plus 60 mg codeine
Study: 3556263
Drug: 650 mg
Normalized name: bran 650 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 650 mg paracetamol plus 65 mg dextropropoxyphene
Study: 31604674
Drug: Ongoing Benzodiazepine
Normalized name: 1,3-dihydro-7-nitro-5-phenyl-2H-1,4-benzodiazepin-2-one
DrugBank: Nitrazepam (DB01595)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ongoing Benzodiazepine and related drug (BDZR) use
Study: 29214506
Drug: Oral paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral paracetamol (1000 mg) co-administered with morphine (0.125 mg/kg)
Study: 29214506
Drug: Intravenous paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous paracetamol (1000 mg) co-administered with morphine (0.125 mg/kg)
Study: 29214506
Drug: Oral paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral paracetamol (1000 mg) after discontinuation of morphine
Study: 25727536
Drug: Antipsychotics (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotics (various types, including olanzapine)
Study: 19738145
Drug: On-treatment IMT
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: On-treatment IMT values
Study: 19738145
Drug: Treatment-induced IMT
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-induced IMT changes
Study: 20080918
Drug: IA injection
Normalized name: factor VIIa Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: IA injection of 40 mg triamcinolone acetonide
Study: 20080918
Drug: 1 cc
Normalized name: BD Needle SG 1 cc 27g 5/8"
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 cc 0.9% saline (placebo)
Study: 19003741
Drug: Autologous bone
Normalized name: Human autologous bone marrow derived osteoblastic cells
DrugBank: Human autologous bone marrow derived osteoblastic cells (DB18259)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous bone marrow cell treatment (injected at 40 sites into the ischemic limb)
Study: 19003741
Drug: Placebo (sham
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (sham bone marrow punction and 40 saline injections)
Study: 19003741
Drug: Autologous bone
Normalized name: Human autologous bone marrow derived osteoblastic cells
DrugBank: Human autologous bone marrow derived osteoblastic cells (DB18259)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous bone marrow cell treatment
Study: 30924301
Drug: Subcision, needling,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcision, needling, and topical application of PRP
Study: 25819042
Drug: Inosine pranobex
Normalized name: inosine pranobex
DrugBank: Inosine pranobex (DB13156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inosine pranobex (1 g four times daily)
Study: 25819042
Drug: Acyclovir (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir (200 mg five times daily)
Study: 21594560
Drug: Valproic acid
Normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valproic acid (400 mg)
Study: 21594560
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of D-cycloserine and Valproic acid
Study: 11535952
Drug: Cefaclor (375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor (375 mg BID for 10 days)
Study: 11535952
Drug: Amoxicillin/clavulanate (625
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/clavulanate (625 mg BID for 10 days)
Study: 9692813
Drug: 10 microg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 microg/kg G‐CSF
Study: 9692813
Drug: 24 microg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 microg/kg G‐CSF
Study: 8778145
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid (AA) 1000 mg daily for 4 weeks
Study: 7276678
Drug: Group A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: MFC (mitomycin C, 5 fluorouracil, cytosine arabinoside) intravenously for 5 weeks, followed by oral 5 FU dry syrup for 2 years
Study: 7276678
Drug: Group C:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C: no chemotherapy added to surgery
Study: 24164569
Drug: SRP +
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SRP + probiotic (Lactobacillus reuteri lozenges, used two times a day for 12 weeks)
Study: 20146674
Drug: Rosuvastatin 10
Normalized name: rosuvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 10 mg/day (n=19)
Study: 20146674
Drug: Atorvastatin 40
Normalized name: atorvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 40 mg/day (n=19)
Study: 16889324
Drug: Individual art
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual art therapy for 1 hour/week during postoperative radiotherapy
Study: 12911442
Drug: Multimodal smoking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal smoking cessation intervention (individual counseling + optional nicotine replacement therapy)
Study: 11004357
Drug: Glyceryl trinitrate
Normalized name: Glyceryl trinitrate
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glyceryl trinitrate (500-microg tablet vaginally, every 6 hours for maximum of two doses)
Study: 11004357
Drug: Prostaglandin E2
Normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 (3-mg tablet vaginally, every 6 hours for maximum of two doses)
Study: 1903167
Drug: rt-PA2 (2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: rt-PA2 (2000 x 10(4)IU, 33 mg)
Study: 1903167
Drug: rt-PA3 (3000
Approvals — FDA: no, EMA: no, PMDA: no
Description: rt-PA3 (3000 x 10(4)IU, 50 mg)
Study: 19882056
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg oral palm vitamin E
Study: 19882056
Drug: 1.5 g
Normalized name: Vaporizer Vicks 1.5 gal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g oral glucosamine sulphate
Study: 17492948
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg of 17beta‐oestradiol orally combined with 100 mg progesterone
Study: 17492948
Drug: 50 microg
Normalized name: Digoxin 250 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 microg of 17beta‐oestradiol transdermally combined with 100 mg progesterone
Study: 11499745
Drug: Aerobic exercise
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerobic exercise (daily walking)
Study: 9923414
Drug: Tacrolimus (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrolimus (target concentration range 10-30 ng/mL during the first 8 weeks, tapering 20% per month during months 3-6)
Study: 9923414
Drug: Cyclosporine (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine (target concentration range 150-450 ng/mL during the first 8 weeks, tapering 20% per month during months 3-6)
Study: 9923414
Drug: Tacrolimus and
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus and Cyclosporine (both treatments)
Study: 27147120
Drug: 50,000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50,000 IU oral vitamin D weekly for eight weeks
Study: 27147120
Drug: Placebo weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo weekly for eight weeks
Study: 19093003
Drug: Rotating cuboid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotating cuboid (non-biological object)
Study: 8471899
Drug: 3-day norfloxacin
Normalized name: Norfloxacin
DrugBank: Norfloxacin (DB01059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-day norfloxacin treatment
Study: 8471899
Drug: 7-day norfloxacin
Normalized name: Norfloxacin
DrugBank: Norfloxacin (DB01059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 7-day norfloxacin treatment
Study: 31368271
Drug: Acupuncture at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture at Sifeng (EX-UE10) combined with Wang's Baochi Pills
Study: 31368271
Drug: Wang's Baochi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wang's Baochi Pills only (Control)
Study: 20060162
Drug: 800 mcg
Normalized name: Biotin 800 MCG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mcg sublingual misoprostol
Study: 20060161
Drug: 40 IU
Normalized name: Oxytocin 40 IU/1 ML Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 IU intravenous oxytocin
Study: 8749950
Drug: CISCA chemotherapy
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CISCA chemotherapy with rhG-CSF (lenograstim) at 2 mg/kg/day subcutaneously on days 3 to 16 (until day 14 for the 14-day interval group)
Study: 8749950
Drug: CISCA chemotherapy
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CISCA chemotherapy with rhG-CSF
Study: 2611119
Drug: H2 A
Normalized name: Influenza A virus H2 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: H2 A + RF alginate antacid (Riflux Forte)
Study: 2611119
Drug: H2 A
Normalized name: Influenza A virus H2 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: H2 A + S non‐alginate antacid (Siloxogene)
Study: 25740264
Drug: Glutamine supplementation
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glutamine supplementation (10 g orally once a day for 3 weeks after initial testing)
Study: 24579364
Drug: Medication (Sanqi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication (Sanqi Tongshu capsules)
Study: 20466870
Drug: Varenicline (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline (0.5 mg once daily for days 1-7, 0.5 mg twice daily for days 8-14, 1 mg twice daily for days 15-21)
Study: 20466870
Drug: Varenicline (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline (0.5 mg once daily for days 1-14, 0.5 mg twice daily for days 15-21)
Study: 20466870
Drug: Varenicline (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline (0.5 mg once daily for days 1-14, 1 mg once daily for days 15-21)
Study: 15888152
Drug: Infliximab 3
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab 3 mg kg(‐1)
Study: 15888152
Drug: Infliximab 5
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab 5 mg kg(‐1)
Study: 16618781
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of nonsteroidal anti-inflammatory drugs
Study: 12456509
Drug: Intensified chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified chemotherapy followed by myeloablative therapy (cyclophosphamide, total body irradiation, and autologous stem cell reinfusion)
Study: 12456509
Drug: Intensified chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified chemotherapy alone (intermediate-dose melphalan [IDM] without stem cell rescue)
Study: 12456509
Drug: Intensified chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified chemotherapy followed by myeloablative therapy
Study: 12456509
Drug: Intensified chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified chemotherapy alone
Study: 11197214
Drug: Am80 therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Am80 therapy
Study: 11197214
Drug: Am80 therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Am80 therapy with subsequent HLA-matched allogeneic bone marrow transplantation (BMT)
Study: 11197214
Drug: Am80 therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Am80 therapy without BMT
Study: 8899270
Drug: Oral tetrathiomolybdate
Normalized name: Tetrathiomolybdate
DrugBank: Tetrathiomolybdate (DB05088)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tetrathiomolybdate (TM) followed by oral zinc (Zn) maintenance therapy
Study: 29710212
Drug: Hyaluronidase (1.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyaluronidase (1.5, 3.0, or 9.0 U per 0.1 mL)
Study: 20646412
Drug: Zhibitai (480
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zhibitai (480 mg orally twice a day)
Study: 20646412
Drug: Atorvastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (10 mg orally once daily)
Study: 20646412
Drug: Zhibitai and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zhibitai and Atorvastatin (both groups)
Study: 14586167
Drug: Naftidrofuryl (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naftidrofuryl (400 mg and 600 mg)
Study: 9280995
Drug: Methadone (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone (5 mg methadone/5 ml saline) applied to the dura before the end of surgery
Study: 31809403
Drug: Intravenous cocaine
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cocaine (10, 20, and 40 mg administered over 2 minutes)
Study: 31809403
Drug: Single-blind placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-blind placebo treatment
Study: 29486598
Drug: New X-ray
Normalized name: lactose, x-ray exposed (1000 rad)
Approvals — FDA: no, EMA: no, PMDA: no
Description: New X-ray imaging platform (AlluraClarity) with reduced dose settings
Study: 26644222
Drug: Micronutrient-fortified LNS
Normalized name: thiamine
DrugBank: Thiamine (DB00152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Micronutrient-fortified LNS with milk protein base (54 g/day)
Study: 26644222
Drug: Micronutrient-fortified LNS
Normalized name: thiamine
DrugBank: Thiamine (DB00152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Micronutrient-fortified LNS with soya protein base (54 g/day)
Study: 26644222
Drug: Micronutrient-fortified corn-soya
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronutrient-fortified corn-soya blend (71 g/day)
Study: 24445981
Drug: Chloral hydrate
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloral hydrate and hydroxyzine (40 mg/kg + 2 mg/kg)
Study: 24445981
Drug: Chloral hydrate
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloral hydrate and promethazine (40 mg/kg + 1 mg/kg)
Study: 12637460
Drug: Cyclophosphamide (C)
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide (C) 600 mg/m(2) + Doxorubicin (A) 60 mg/m(2)
Study: 12637460
Drug: Cyclophosphamide (C)
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide (C) 600 mg/m(2) + Doxorubicin (A) 75 mg/m(2)
Study: 12637460
Drug: Cyclophosphamide (C)
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide (C) 600 mg/m(2) + Doxorubicin (A) 90 mg/m(2)
Study: 12637460
Drug: Cyclophosphamide (C)
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide (C) + Doxorubicin (A) + Paclitaxel (175 mg/m(2))
Study: 10758778
Drug: Artichoke dry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artichoke dry extract (1,800 mg per day)
Study: 8836707
Drug: Itraconazole 200
Normalized name: itraconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole 200 mg a day for 4 days
Study: 1316058
Drug: Amoxicillin 500
Normalized name: amoxicillin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin 500 mg every 8 hours
Study: 4077578
Drug: Multivitamin and
Normalized name: Multivitamin and Minerals Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multivitamin and iron supplement (twice weekly)
Study: 21900849
Drug: Flaxseed bar
Normalized name: FLAXSEED
DrugBank: Flax seed (DB10708)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flaxseed bar (410 mg of lignans) for 6 weeks
Study: 20441245
Drug: Fentanyl buccal
Normalized name: Fentanyl Buccal Film
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl buccal tablet (FBT) 600 microg
Study: 20441245
Drug: Fentanyl buccal
Normalized name: Fentanyl Buccal Film
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl buccal tablet (FBT) 1000 microg
Study: 20441245
Drug: Fentanyl buccal
Normalized name: Fentanyl Buccal Film
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl buccal tablet (FBT) 1200 microg
Study: 20441245
Drug: Fentanyl buccal
Normalized name: Fentanyl Buccal Film
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl buccal tablet (FBT) 1300 microg
Study: 16240707
Drug: Winex (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Winex (100 mg/5 ml) suspension
Study: 16240707
Drug: Suprax (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suprax (100 mg/5 ml) suspension
Study: 8576506
Drug: Self-medication program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-medication program (SMP)
Study: 1672895
Drug: Generic carbamazepine
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Generic carbamazepine (100 and 200 mg tablets)
Study: 7019268
Drug: 0.2% aqueous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% aqueous solution of chlorhexidine gluconate
Study: 31194598
Drug: Six Dried
Normalized name: peptone,dried
Approvals — FDA: no, EMA: no, PMDA: no
Description: Six Dried Plums (∼42 g) per day for 2 weeks
Study: 31194598
Drug: Two Dried
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two Dried Plums (∼14 g) per day for 2 weeks
Study: 23224687
Drug: Resveratrol-containing grape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol-containing grape extract (8 mg resveratrol)
Study: 18474729
Drug: Naproxen sodium
Normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen sodium (220 mg twice daily)
Study: 17000818
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine (0.5 mg) and fentanyl (15 microg)
Study: 17000818
Drug: Sham intrathecal
Normalized name: beractant
DrugBank: Beractant (DB06761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sham intrathecal injection (placebo)
Study: 12562833
Drug: FAT (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: FAT (50 g/m2)
Study: 12562833
Drug: GLUCOSE (37.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLUCOSE (37.5 g/m2)
Study: 12562833
Drug: MIXED test
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: MIXED test (combination of FAT and GLUCOSE)
Study: 9013365
Drug: Sirolimus (rapamycin)
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus (rapamycin) at dosage levels from 1 mg/m2/day to 13 mg/m2/day
Study: 1392995
Drug: Omeprazole for
Normalized name: omeprazole Granules for Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole for four weeks plus bismuth 120 mg, tetracycline 500 mg, and metronidazole 400 mg (all four times a day) for the first week (n = 78)
Study: 29127137
Drug: Analytic Treatment
Normalized name: CATALYTIC FORMULA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analytic Treatment Interruption (ATI)
Study: 26847108
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) with additional synthetic disease modifying anti‐rheumatic drugs (sDMARDs)
Study: 23447917
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg Pycnogenol twice daily for 3 months
Study: 21904014
Drug: Autologous bone
Normalized name: Human autologous bone marrow derived osteoblastic cells
DrugBank: Human autologous bone marrow derived osteoblastic cells (DB18259)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous bone marrow-derived cells (5 cc)
Study: 21904014
Drug: Whole blood
Normalized name: Whole blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole blood (5 cc)
Study: 18498663
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg omeprazole or 20 mg rabeprazole for 8 days (treatment group)
Study: 12713711
Drug: Low-dose acetazolamide
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose acetazolamide (125 mg BID)
Study: 11498723
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg NF
Study: 11498723
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg NF